Drugs | Mode of action | Effects | Adverse side effects | Refs. |
---|---|---|---|---|
L-DOPA | Dopamine agonist | Increases dopamine concentrations | Nausea, vomiting, low blood pressure, restlessness, drowsiness. | |
Selegiline | MAO-B inhibitor | Maintains L-DOPA levels | Dizziness, dry mouth, insomnia, muscle pain, rash, nausea, constipation, severe headache, tachycardia, arrhythmia, hallucinations, chorea, or difficulty in breathing. | [326] |
Creatine | Boosts mitochondrial function | Antioxidant, prevents MPTP-induced neuronal damage | Nausea, stomach pain, diarrhea, muscle cramps; difficult breathing; swelling of face, lips, tongue, or throat, and weight gain. | [327] |
Bromocriptine, Apomorphine, Pramipexole, Rropinirole | Dopamine agonist | Increases dopamine levels | Drowsiness, nausea, vomiting, dry mouth, dizziness, leg swelling, and feeling faint upon standing, drop in blood pressure, confusion, hallucinations, or psychosis. | [328] |
Entacapone and tolcapone | preventing the breakdown of dopamine | prolongs the effects of L-DOPA | Hepatotoxic, nausea, diarrhea, orthostatic hypotension, urine discoloration and dizziness, mitochondrial dysfunction, | [329] |
Amantidine | Activate dopamine synthesis | Increases dopamine levels | Blurred vision, confusion, difficult urination, dizziness, fainting seeing, and hearing, swelling of the hands, feet, or lower legs. | [330] |
Rofecoxib | Inhibit COX-2 | Prevents inflammation | Back pain, diarrhea, dizziness, headache, heartburn, and loss of energy or weakness, nausea, stuffy or runny nose, swelling of legs and feet, blurred vision, constipation. | [331] |
ACP-103 (Pimavanserin) | Blocks serotonin receptors | Decrease levodopa-associated complications | Hyperprolactinemia, menstrual and sexual dysfunction, akathisia, distressful motor disturbance, restlessness | [332] |
GM1 gangliosides | Dimerization of tyrosine kinase A and increases neurotropic factors | Increases dopamine | Not known | [333] |
Quetiapine | Blocking of the dopamine type 2 (D2) and serotonin type 2 (5-HT2) receptors | Reduce psychosis and/or agitation | Agitation, dizziness, tremor, anxiety, hypertonia, abnormal dreams, dyskinesia, involuntary movements, confusion, amnesia, hyperkinesia, increased libido, abnormal gait, myoclonus, apathy, ataxia, hemiplegia, aphasia, buccoglossal syndrome | [334] |
Ubiquinone or coenzyme Q10 | Improves mitochondrial function | Antioxidant, slows disease progression in early-stages | Lower blood pressure, hemorrhage, skin itching, nausea, vomiting, headache or migraines, abnormal breathing, back pain, bronchitis, changes in attention, chest pain, constipation, coughing, diarrhea, dizziness, fainting, falling, fatigue, hearing loss, heart attack, indigestion, insomnia, irritability, loss of appetite, low energy, muscle pain, night sweats, respiratory tract infection, sore throat, urinary infection etc. | |
S-Adenosyl-methionine (SAM) | Methylates phospholipid and increase nerve-cell communication | Improves dopamine transmission, decreases depression | Gastrointestinal disorders, dyspepsia, and anxiety. | [337] |
Entacapone, tolcapone | COMT inhibitors | Inhibit DA breakdown | Diarrhea, nausea, sleeps disturbances, dizziness, urine discoloration, abdominal pain, low blood pressure, hallucinations. | [338] |